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Abstract:
Background: Systemic lupus erythematous (SLE) is a systemic 
autoimmune/inflammatory condition. Approximately 15-20% of patients 
develop symptoms before their 18th birthday and are diagnosed with 
juvenile-onset SLE (JSLE). Gender distribution, clinical presentation, 
disease courses and outcomes vary significantly between JSLE patients 
and individuals with adult-onset SLE. This study aimed to identify age-
specific clinical and/or serological patterns in JSLE patients enrolled to 
the UK JSLE Cohort Study. 
Methods: Patient records were accessed and grouped based on age at 
disease-onset: pre-pubertal (≤7 years), peri-pubertal (8-13 years) and 
adolescent (14-18 years). The presence of ACR classification criteria, 
laboratory results, disease activity (BILAG and SLEDAI-2K scores) and 
damage (SLICC damage index) were evaluated at diagnosis and last 
follow-up. 
Results: A total of 418 JSLE patients were included in this study: 43 
(10.3%) with pre-pubertal disease onset; 240 (57.4%) with peri-
pubertal onset, and 135 (32.3%) were diagnosed during adolescence. At 
diagnosis, adolescent JSLE patients presented with a higher number of 
ACR criteria when compared to pre-pubertal and peri-pubertal patients 
(pBILAG2004 scores: 9[4-20] vs. 7[3-13] vs. 7[3-14] respectively, 
p=0.015) with increased activity in the following BILAG domains: 
mucocutaneous (p=0.025), musculoskeletal (p=0.029), renal (p=0.027), 
and cardiorespiratory (p=0.001). Furthermore, adolescent JSLE patients 
were more frequently ANA positive (p=0.034) and exhibited higher anti-
dsDNA titres (p=0.001). Pre-pubertal individuals less frequently 
presented with leukopenia (p=0.002), thrombocytopenia (p=0.004) or 
low complement (p=0.002) when compared to other age groups. No 
differences were identified in disease activity (pBILAG2004 score), 
damage (SLICC damage index) and the number of ACR criteria fulfilled 
at last follow-up. 
Conclusions: Disease presentations and laboratory findings vary 
significantly between age groups within a national cohort of JSLE 
patients. Patients diagnosed during adolescence exhibit greater disease 
activity and “classic” autoantibody, immune cell and complement 
patterns when compared to younger patients. This supports the 
hypothesis that pathomechanisms may vary between patient age 
groups.
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Abstract
Background: Systemic lupus erythematous (SLE) is a systemic autoimmune/inflammatory 
condition. Approximately 15-20% of patients develop symptoms before their 18th birthday and 
are diagnosed with juvenile-onset SLE (JSLE). Gender distribution, clinical presentation, 
disease courses and outcomes vary significantly between JSLE patients and individuals with 
adult-onset SLE. This study aimed to identify age-specific clinical and/or serological patterns 
in JSLE patients enrolled to the UK JSLE Cohort Study. 
Methods: Patient records were accessed and grouped based on age at disease-onset: pre-
pubertal (≤7 years), peri-pubertal (8-13 years) and adolescent (14-18 years). The presence of 
ACR classification criteria, laboratory results, disease activity (BILAG and SLEDAI-2K 
scores) and damage (SLICC damage index) were evaluated at diagnosis and last follow-up.
Results: A total of 418 JSLE patients were included in this study: 43 (10.3%) with pre-pubertal 
disease onset; 240 (57.4%) with peri-pubertal onset, and 135 (32.3%) were diagnosed during 
adolescence. At diagnosis, adolescent JSLE patients presented with a higher number of ACR 
criteria when compared to pre-pubertal and peri-pubertal patients (pBILAG2004 scores: 9[4-
20] vs. 7[3-13] vs. 7[3-14] respectively, p=0.015) with increased activity in the following 
BILAG domains: mucocutaneous (p=0.025), musculoskeletal (p=0.029), renal (p=0.027), and 
cardiorespiratory (p=0.001). Furthermore, adolescent JSLE patients were more frequently 
ANA positive (p=0.034) and exhibited higher anti-dsDNA titres (p=0.001). Pre-pubertal 
individuals less frequently presented with leukopenia (p=0.002), thrombocytopenia (p=0.004) 
or low complement (p=0.002) when compared to other age groups. No differences were 
identified in disease activity (pBILAG2004 score), damage (SLICC damage index) and the 
number of ACR criteria fulfilled at last follow-up.
Conclusions: Disease presentations and laboratory findings vary significantly between age 
groups within a national cohort of JSLE patients. Patients diagnosed during adolescence exhibit 
greater disease activity and “classic” autoantibody, immune cell and complement patterns 
when compared to younger patients. This supports the hypothesis that pathomechanisms may 
vary between patient age groups.
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Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune/inflammatory condition that 
can affect any organ system and result in significant damage and organ failure1, 2. Clinical 
characteristics, underlying pathomechanisms, disease progression and outcomes vary between 
individuals, age groups and races. Approximately 15-20% of SLE patients develop the disease 
before their 18th birthday and are therefore diagnosed with juvenile-onset SLE (JSLE)1, 2. 
Juvenile onset-disease is associated with more severe organ involvement (including renal and 
CNS disease), increased disease activity, presence of greater damage at the time of diagnosis, 
and higher steroid burden, contributing to the increased morbidity and mortality when 
compared to adult-onset SLE 3-5.  Even within the JSLE population, very early disease onset 
(before the 5th birthday) may be associated with atypical presentations (including fewer 
autoantibodies), more severe disease courses and poor prognosis1, 6-8. However, assumptions 
on variable disease presentation and progression within different JSLE age sub-groups are 
generally based on case reports, case series or relatively small cohorts7, 8 and currently lack 
scientific evidence from longitudinal national or international studies. 
Preliminary datasets suggest that clinical differences may reflect variable pathomechanisms 
and that patients with JSLE may have increased genetic burden when compared to individuals 
with adult-onset disease, contributing to early dis ase onset and more severe presentations1, 9. 
Very early disease onset, atypical disease presentation and severe manifestations may be the 
result of (very rare) disease-causing mutations in single genes or the combination of multiple 
genomic variants that individually increase an individual’s risk for the development of SLE1, 9-
11. To date, evidence still remains weak and it is largely unclear whether distinct clinical and 
laboratory differences exist between age groups within the paediatric population1, 12, 13.
This study aimed to assess if there are differential clinical and laboratory characteristics in 
patients presenting with JSLE at different ages, sub-dividing patients into three groups: pre-
pubertal (≤7 years), peri-pubertal (8-13 years) or adolescence (14-18 years). To achieve this, 
prospectively collected data from a national cohort of JSLE patients (the UK JSLE Cohort 
Study) was interrogated. 
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Methods
Patients  
Participants of the UK JSLE Cohort Study14, followed between 2006-2018, aged 16 years at 
the time of diagnosis and with ≥4 American College of Rheumatology (ACR) classification 
criteria for SLE 15 were included in this study. Participants were excluded from the study if 
they did not have a diagnosis date recorded, as this precluded them from being categorized on 
the basis on their age at disease-onset (pre-pubertal (≤7 years), peri-pubertal (8-13 years) or 
adolescent (14-18 years)). Patient/family reported ethnicity information was collected using 
the UK National Census categorisations12. Data of patients who were of mixed race were 
grouped with those of the associated ethnic minority group (e.g. Asian if mixed Asian and 
Caucasian race). Of note, distribution among ethnicities did not vary between age groups (see 
results section, supplement tables 1&2).
Data collected
The following clinical and laboratory data were collected: 1) total ACR score with its 
individual domains15; 2) anti-nuclear antibody (ANA) positivity and titre; 3) Systemic Lupus 
International Collaborating Clinics standardised damage index (SLICC-SDI) score16; 4) 
SLEDAI-2K score17 5) paediatric British Isles Lupus Assessment Grade 2004 numerical scores 
(pBILAG2004) with individual organ/system domains (alphabetical score A-E)18; 6) key 
laboratory findings, including haemoglobin levels, white cell count and differentiation, 
platelets, erythrocyte sedimentation rate (ESR), complement levels (C3, C4) and anti-double-
stranded DNA (dsDNA) titres
The SLICC-SDI tool records permanent damage that occurs as a result of SLE activity, and is 
composed of 41 different components16.  The SLEDAI- score is a widely used measure of lupus 
disease activity providing numerical scores based on a count of laboratory and clinical 
symptoms17. The pBILAG2004 score is a composite disease activity measure focusing on nine 
organ/system domains (constitutional, mucocutaneous, neurological, musculoskeletal, 
cardiovascular/respiratory, renal, gastrointestinal, ophthalmic and haematological). Each organ 
domain is graded A-E and defined as follows; pBILAG2004 grade A/B: severe and moderate 
disease respectively, grade C patients: mild/improving renal disease, grade D: inactive disease 
but previous system involvement, grade E: system has never been involved19, 20. For each 
organ/system domain, an alphabetical (A-E grade) is determined, equating to a numerical value 
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for each organ/system domain. These can be combined to give the total numerical 
pBILAG2004 score18. Within these analyses, presence of pBILAG2004 domains A and B was 
taken to signify active organ/system involvement, in-keeping with previous studies18. All data 
items (1-5 listed above) were collected at the time of initial diagnosis. At the patients’ last 
follow-up visit, data from items 1 and 4 were collected. Furthermore, data from item 5 were 
collected from patients as their cumulative maximum disease activity level (for each individual 
organ/system domain) throughout the disease course.
Statistical analysis 
Laboratory findings, total number of ACR criteria, SLICC, SLEDAI-2K and pBILAG2004 
scores were compared between groups using Kruskal-Wallis tests. Median values and 
interquartile ranges (IQRs) are displayed within tables. Categorical pBILAG2004 domain data 
is presented as a percentage of patients with active organ/system involvement for each age 
group along with 95% confidence intervals. Individual domains of the pBILAG2004 score 
were compared between groups using Chi-square and Fisher’s exact tests. Analyses were 
completed using SPSS software, version 25 (IBM SPSS).
Power analysis revealed that the three patient groups should all have approximately 700 
patients each to reach sufficient statistical power. Limited by the rarity of JSLE and resulting 
number of patients included in the national UK JSLE cohort study since 2006, these numbers 
are  extremely difficult to obtain in national or even international cohorts. Thus, p values of 
statistical tests should be interpreted with caution, based upon the limited statistical power of 
this study.
Ethics
Written patient assent/consent and/or where appropriate parental consent was obtained for 
inclusion of patients within the UK JSLE Cohort Study. The UK JSLE Cohort Study has full 
ethical approval from the National Research Ethics Service North West, Liverpool East (REC 
reference 06/Q1502/77). This research was carried out in accordance with the decleration of 
Helsinki.
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Results
Demographics 
A total of 418 eligible patients enrolled in the UK JSLE Cohort Study were included in this 
study; five JSLE patients were excluded due to unknown age at diagnosis. The mean age at 
diagnosis was 12.1 years (range: 0.17-17.91), with 43/418 (10.3%) participants presenting in 
the pre-pubertal period, 240/418 (57.4%) were peri-pubertal, and 135/418 (32.3%) were in the 
adolescent age group. The overall female:male ratio was 5.4:1 and increased with age (pre-
pubertal=3.3:1; peri-pubertal=5.24:1; adolescent=7.25:1). No statistically significant 
differences were demonstrated between groups in relation to ethnicity (p>0.05) (supplement 
tables 1 and 2).
Clinical features 
At diagnosis, adolescent JSLE patients exhibited higher median ACR scores when compared 
to younger JSLE patients (pre-pubertal: median 4[IQR 4-5] vs. peri-pubertal: 4[4-5] vs. 
adolescent: 5[4-6], p=0.004). Similarly, pBILAG2004 disease activity scores were higher in 
newly diagnosed adolescent JSLE patients (pBILAG2004: 9[4-20]) when compared to younger 
JSLE patients (pre-pubertal: 7[3-13]; peri-pubertal: 7[3-14], p = 0.015) (Table 1). First 
SLEDAI-2K scores were also higher in the adolescent population (pre-pubertal: 8[4-14]; peri-
pubertal 8[4-14]; adolescent 12[6-18], p = 0.001) (Table 1). Furthermore, adolescents with a 
new diagnosis of JSLE exhibited more activity in the following pBILAG domains when 
compared to new peri-pubertal and pre-pubertal JSLE patients: mucocutaneous (p=0.025), 
musculoskeletal (p=0.029), cardiorespiratory (p=0.001) and renal (p=0.027) (Table 1).
At the time of last follow-up differences were not apparent between age groups in terms of 
total ACR scores (median of 5[IQR 4-7] in all groups), disease activity shown through 
SLEDAI-2K (pre-pubertal: 8[5-8]; peri-pubertal: 8[6-8]; adolescent 7[5-8], p=0.689) or ANA 
positivity. Over the disease course active organ/system involvement (as defined by the 
pBILAG2004 score) also did not differ significantly between age groups (Table 2). There was 
little variance in SLICC-SDI defined damage at diagnosis (p=0.410) or last follow-up 
(p=0.284) between age groups (Tables 1 and 2).
Laboratory features
Laboratory findings varied between JSLE patients from different age groups at diagnosis 
(Table 3). White blood cell and platelet counts reduced with growing age across the JSLE 
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cohort; with pre-pubertal patients exhibiting median white cell counts of 6.7x10⁹/L [4.69 – 
9.53] vs. 6.09x10⁹/L [4.16-8.67] in peri-pubertal vs. 4.69x10⁹/L [3.7-6.54] in the adolescent 
age group (p=0.002). Median platelet counts were within the normal range, but followed a 
similar pattern to the white cell count, with 293x10⁹/L [212-426] in the pre-pubertal group vs. 
271x10⁹/L [191-388] in the peri-pubertal vs. 242x10⁹/L [168-298] in the adolescent group 
(p=0.004). Median levels of haemoglobin (p=0.404) and ESR (p=0.2) did not differ between 
age groups (Table 3).
Serum complement is a measure of disease activity in SLE as it indicates activation and 
consumption of complement components21. Median complement levels differed significantly 
between age groups, with higher complement levels in younger patients (C3: 0.95g/L [0.73-
1.11] in pre-pubertal patients vs. 0.81g/L [0.50-1.22] in peri-pubertal vs. 0.69g/L [0.28-0.98] 
in adolescent patients (p=0.002); C4: 0.13g/L [0.08-0.28] in pre-pubertal patients vs. 0.11g/L 
[0.06-0.19] peri-pubertal patients vs. 0.08g/L [0.04-0.14] in adolescent patients (p=0.002)) 
(Table 3).
In the UK JSLE cohort, patients with disease-onset during adolescence were more frequently 
ANA positive 131/135 (97.0%) at diagnosis, when compared to the other age groups; 37/43 
(86.0%) with pre-pubertal onset, and 223/240 (92.9%) in peri-pubertal onset (p=0.034). Anti-
dsDNA antibody titres were higher in older patients than younger patients; pre-pubertal onset 
15 IU/L [0.25-89] vs. 67 IU/L [19-200] in peri-pubertal group vs. 111 IU/L [15-300] in 
adolescents (p=0.001) (Table 3).
Discussion
While clinical and laboratory differences between JSLE and adult-onset SLE have been 
acknowledged 8, only few and short reports discuss differences within the paediatric age 
group12, 13. The 418 JSLE patients included in this study allow for more reliable assessment of 
clinical and laboratory features between the paediatric age groups. When compared to younger 
children, adolescents exhibit an increased number of ACR criteria, and show typical 
autoantibody patterns (ANA and anti-dsDNA positivity), haematological involvement 
(leukopenia, thrombocytopenia) and immunological characteristics (hypocomplementaemia) 
reflecting “classical” SLE. Of note, adolescents also present with higher disease activity at 
diagnosis when compared to younger children (total numerical BILAG score, p=0.015; and 
SLEDAI-2K scores, p=0.001). At diagnosis, differences were also seen in the organ domains 
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involved across age groups, including increased mucocutaneous, musculoskeletal, 
cardiorespiratory and renal system involvement in adolescents when compared to other age 
groups. Notably, previous studies did not consider pre-pubertal (≤7) JSLE patients as a distinct 
age group3, 6-8.
One of the most interesting differences between JSLE patients within the three age groups 
relates to laboratory findings. Patients diagnosed in early childhood (≤7 years) had lower rates 
of ANA positivity, with 14% of the pre-pubertal JSLE patients being ANA negative vs. 3% of 
the adolescent JSLE group (p=0.034). Pre-pubertal children also displayed lower median anti-
dsDNA titres than the other age groups (p=0.001). These laboratory differences may reflect 
differences in pathophysiology at varying ages, and a potentially more “innate” disease 
phenotype in at least a subset of early-onset JSLE patients1. 
Of note, previous studies failed to identify serological differences between paediatric and adult 
SLE populations, which may be due to them not discriminating between age groups within the 
JSLE population3, 8, 22.  This potential explanation is supported by the observation that 
differences in immunological patterns (ANA positivity) disappeared by the time of last follow 
up prior to transition into adult care (p=0.559). Most patients who were initially autoantibody 
negative in the pre-pubertal (11.7%) and peri-pubertal age groups (2.9%), eventually developed 
ANA positivity (pre-pubertal group: 14% at diagnosis vs. 2% at last follow up) between the 
time of initial diagnosis and last follow-up. It has previously been discussed that early-onset 
JSLE patients, who may have a higher genetic risk when compared to older SLE patients or 
have a more monogenic disease phenotype, can develop autoantibodies over time as a result of 
tissue damage and subsequent presentation of physiologically nuclear components to the 
immune system1, 23.
This study also found increased frequencies of ANA positivity to coincide with an increased 
prevalence of likely autoantibody-mediated symptoms, e.g. renal, musculoskeletal and 
haematological anomalies (thrombocytopenia, lymphopenia and low complement levels, all 
p<0.05). Autoantibodies (particularly anti-dsDNA antibodies) indeed contribute to renal 
disease and immune complex deposition, which may also partially cause the pathologically 
reduced complement levels observed with increasing age2, 21, 24. Also, increased 
musculoskeletal involvement in adult-onset SLE vs. JSLE patients has been previously 
demonstrated 3, 8, 13. Tavangar-Rad et al. studied 120 Iranian children with JSLE and compared 
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age groups in a similar way to the current study (<7, 7-14, and >14 years) and reported more 
joint involvement with increasing age13. While it remains unclear why this is, musculoskeletal 
involvement is another example of a clinical feature that may be auto-antibody driven, thus 
becoming more prevalent with advancing age at presentation. 
Findings from this study also suggest that disease activity within the paediatric age group may 
(at diagnosis) be more severe in individuals diagnosed in adolescence, while disease severity 
increases over time in children diagnosed at a younger age. This is indicated by comparable 
disease activity and damage scores at last follow up. Based on variable clinical patterns over 
time that coincide with increased disease activity, autoantibodies, immune complex deposition, 
and complement activation may likely be involved in this process2, 21, 24. Differences between 
the present study and previous reports suggesting increased disease severity in very early-onset 
SLE when compared to “older” children with JSLE, may be due to the character of previous 
reports 12. Small case series and individual case reports tend to over-report particularly severe, 
interesting and/or complicated presentations and disease courses. 
The absence of ANA antibodies in 14% of pre-pubertal JSLE patients is interesting when 
considering the classification criteria for SLE. ecently proposed “new” ACR/EULAR criteria 
for SLE include ANA titres of ≥1:80 as entry criterion25. While application of these criteria 
would only affect a relatively small number of peri-pubertal or adolescent JSLE patients, 14% 
of patients with early disease-onset could potentially remain without a diagnosis, as 
classification criteria are frequently (incorrectly) used by colleagues (not necessarily 
specialized in paediatric rheumatology) to diagnose SLE and refer to tertiary care. One may 
argue that very early disease-onset in the absence of autoantibodies can indicate genetic 
conditions (“monogenic SLE-like disease”, such as complement deficiencies, primary type I 
interferonopathies) and that it is beneficial for patients to not be classified as “classical” SLE. 
However, this may result in diagnostic delays and that young patients not being seen by 
paediatric rheumatologists26. 
Although this study involves one of the largest national JSLE cohorts available, it is still limited 
by JSLE being a rare disease and patient numbers. A power analysis performed prior to this 
study suggested that around 700 patients were required per group for the analysis to be 
statistically reliable. Since the UK JSLE cohort study is the largest JSLE cohort across Europe 
and one of the largest in the world, this limitation can unfortunately currently not be addressed. 
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International collaboration is therefore warranted in the future. The variable duration of follow-
up from initial evaluation to last visit between the three age groups may also be seen as a 
potential limitation. This was mainly caused by the time of transition to adult care.
Conclusion
This is the largest study to date comparing clinical and laboratory features of JSLE patients 
diagnosed during the pre- (≤7), peri-pubertal (8-13) and adolescent (14-18) periods. Distinct 
clinical and laboratory differences between age groups support the hypothesis that variable 
pathomechanisms may contribute to differences in clinical presentations, treatment responses 
and disease outcomes not only between adult and paediatric patients but also within the cohort 
of JSLE patients. Based on the presence of autoantibodies and higher prevalence of antibody-
mediated features (including thrombocytopenia, lymphopenia, hypocomplementaemia), 
adaptive immune mechanisms may play an increasing role with growing age.  Disease activity 
at diagnosis is higher in individuals diagnosed in adolescence when compared to younger 
patients. However, disease severity increases over time in children diagnosed at a younger age 
underscoring the importance of tightly monitored and sufficient treatment in a specialized 
centre. Though the largest study of its kind, it is still limited by patient numbers, due to the 
rarity of JSLE. Thus, international collaborations are warranted to address age-specific 
differences in JSLE in more detail.
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Table 1 – Clinical features of JSLE subgroups at diagnosis
Item Pre-pubertal 
disease-onset 
(n=43)
Peri-pubertal 
disease-onset 
(n=240)
Adolescence 
(n=135)
P 
value
Female:Male ratio
3.3:1 5.24:1 7.25:1 0.347
Total ACR score
4 [4-5] 4 [4-5] 5 [4-6] 0.004
SLICC-SDI
0 [0] 0 [0] 0 [0] 0.410
SLEDAI-2K
8 [4-14] 8 [4-14] 12 [6-18] 0.001
Total numerical 
pBILAG2004 score 
7 [3-13] 7 [3-14] 9 [4-20] 0.015
Active organ/system involvement at diagnosis (pBILAG2004 defined)
 Constitutional 13 (30.2%)
[16.5%, 43.9%]
67 (27.9%)
[22.2%, 33.6%]
51 (37.8%)
[29.6%, 46.0%]
0.140
 Mucocutaneous 19 (44.2%)
[29.5%, 59.0%]
78 (32.5%)
(26.6%, 38.4%]
62 (45.9%)
[37.5%, 54.3%]
0.025
 Neuropsychiatric 6 (40.0%)
[25.4%, 54.6%]
20 (8.3%)
[4.8%, 11.8%]
14 (10.4%)
[5.3%, 15.3%]
0.477
 Musculoskeletal 7 (16.3%)
[5.3%, 27.3%]
66 (27.5%)
[21.9%, 33.1%]
49 (36.3%)
[28.2%, 44.4%]
0.029
 Cardiorespiratory 4 (9.3%)
[0.6%, 18%]
18 (7.5%)
[4.2%, 10.8%]
27 (20%)
[13.3%, 26.7%]
0.001
 Gastrointestinal 2 (4.7%)
[0%, 11%]
15 (6.3%)
[3.2%, 9.4%]
4 ((3.0%)
[0.1%, 5.9%]
0.442
 Ophthalmic 1 (2.3%)
[0%, 6.8%]
2 (0.8%)
[0%, 1.9%]
1 (0.7%)
[0%, 2.1%]
0.548
 Renal 9 (20.9%)
[8.7%, 33.1%]
73 (30.4%)
[24.6%, 36.2%]
55 (40.7%)
[32.4%, 49.0%]
0.027
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 Haematological 11 (25.6%)
[12.6%, 38.6%]
58 (24.1%)
[18.7%, 29.5%]
37 (27.4%)
[19.9%, 34.9%]
0.786
Total ACR, SLICC-SDI, SLEDAI-2K, pBILAG2004 scores, and key laboratorial findings are 
reported as median values and interquartile ranges [in square brackets]. For individual 
pBILAG2004 organs/systems involved, the total number of patients with active involvement 
(defined as pBILAG2004 domain score of A or B within a given organ domain/system) is 
provided along with the percentage (in curved brackets) and 95% confidence intervals for the 
percentage [in square brackets].
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Table 2 – Clinical features of the different age groups over time 
Items on last 
follow up
Pre-pubertal 
disease-onset 
(n=43)
Peri-pubertal 
disease-onset 
(n=240)
Adolescence 
(n=135)
P value
Length of follow 
up in years 
6 [3-9] 4 [2-6] 2 [1-4] <0.001
Total ACR score 5 [4-7] 5 [4-7] 5 [4-7] 0.686
SLICC-SDI score 0 [0-1] 0 [0-1] 0 [0-1] 0.284
SLEDAI-2K 8 [5-8] 8 [6-8] 7 [5-8] 0.689
ANA positivity 42 (97.7%)
[93.2%, 102.2%]
230 (95.8%)
[93.3%, 98.3%]
132 (97.8%)
[95.3%, 100.0%]
0.559
pBILAG2004 defined organ/system domain involvement throughout the disease course
Constitutional 18 (41.9%)
[27.2%, 56.6%]
98 (40.8%)
[34.1%, 46.5%]
56 (41.5%)
[33.2%, 49.8%]
0.988
Mucocutaneous 33 (76.7%)
[64.1%, 89.3%]
157 (65.4%)
[59.4%, 71.4%]
90 (66.7%)
[58.7%, 74.7%]
0.346
Neuropsychiatric 11 (25.6%)
[12.6%, 38.6%]
57 (27.9%)
[22.2%, 33.6%]
28 (20.7%)
[13.9%, 27.5%]
0.731
Musculoskeletal 18 (41.9%)
[16.5%, 43.9%]
121 (50.4%)
[44.1%, 56.7%]
73 (54.1%)
[45.7%, 62.5%]
0.374
Cardiorespiratory 13 (30.2%)
[16.5%, 43.9%]
46 (19.2%)
[14.2%, 24.2%]
35 (25.9%)
[18.5%, 33.3%]
0.141
Gastrointestinal 8 (18.6%)
[7.0%, 30.2%]
28 (11.7%)
[7.6%, 15.8%]
10 (7.4%)
[3.0%, 11.8%]
0.107
Ophthalmic 3 (7.0%)
[0%, 14.6%]
12 (5.0%)
[2.2%, 7.8%]
4 (3.0%)
[0.1%, 5.9%]
0.467
Renal 28 (65.1%)
[50.9%, 79.3%]
153 (63.8%)
[57.7%, 69.9%]
94 (69.6%)
[61.8%, 77.4%]
0.513
Hematological 26 (60.5%)
[45.9%, 75.1%]
114 (47.5%)
[41.2%, 53.8%]
55 (40.7%)
[32.4%, 49.0%]
0.072
Total ACR, SLICC-SDI, SLEDAI-2K, pBILAG2004 scores are reported as median values 
and interquartile ranges. For individual pBILAG2004 domains, the total number of patients 
with activity involvement (defined as a pBILAG2004 domain score of A or B in a given 
organ domain/system) are provided along with percentage (in curved brackets), and 95% 
Page 18 of 21
http://mc.manuscriptcentral.com/lupus
LUPUS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
confidence intervals for the percentage [square brackets]. SLICC-SDI and ACR scores are 
provided from the last follow-up visit.
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Table 3 – Laboratory features of JSLE subgroups at diagnosis
Key laboratory 
findings
Pre-pubertal 
disease-onset 
(n=43)
Peri-pubertal 
disease-onset 
(n=240)
Adolescence 
(n=135)
P 
value
Haemoglobin level 
(g/dL)
11 [9-11.9] 11.3 [9.9-12.6] 11.08 [9.7-12.53] 0.404
White cell count 
(x 10⁹/L) 
6.7 [4.69-9.53] 6.09 [4.16-8.67] 4.69 [3.7-6.54] 0.002
Platelets (x 10⁹/L) 293 [212-426] 271 [191-338] 242 [168-298] 0.004
ESR (mm/hr) 18 [11-72] 36 [12-76] 42.5 [19-86.75] 0.200
C3 median (g/L) 0.95 [0.73-1.11] 0.81 [0.50-1.22] 0.69 [0.28-0.98] 0.002
C4 median (g/L) 0.13 [0.08-0.28] 0.11 [0.06-0.19] 0.08 [0.04-0.14] 0.002
ANA positive 37 (86.0%)
[80.7%, 91.3%]
223 (92.9%)
[89.7%, 96.2%]
131 (97.0%)
[94.1%, 99.9%]
0.034
ANA titre median 1:640 
[1:320-1:960]
1:640 
[1:320-1:1280]
1:640 
[1:320-1:2560]
0.565
dsDNA levels (IU/L) 15 [0.25-89] 67 [19-200] 111 [15-300] 0.001
Haemogolobin, white cell count, platelets, ESR, C3, C4, ANA titre and dsDNA titre are 
reported as median values and interquartile ranges [in square brackets]. 
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Supplement table 1 – Ethnicity of participants
Ethnicity
Pre-pubertal 
disease-onset 
(n=43)
Peri-pubertal 
disease-onset 
(n=240)
Adolescence 
(n=135)
P value
British or Irish
19/43 (44.2%)
[29.3%, 59.0%]
104/240 (43.3%)
[37.0%, 49.6%]
77/135 (57.0%) 
[48.7%, 65.4%]
Asian
13/43 (30.2%)
[16.5%, 44.0%]
73/240 (30.4%)
[24.6% ,36.2%]
41/135 (30.4%) 
[22.6%, 38.1%]
African/Caribbean
8/43 (18.6%)
[7.0%, 30.2%]
45/240 (18.8%)
[13.8%, 23.7%]
14/135 (10.4%) 
[5.2%, 15.5%]
Other Caucasian 
origin
1/43 (2.3%)
[-2.2%, 6.8%]
7/240 (2.9%)
[0.8%, 5.0%]
2/135 (1.5%)
[-0.6% ,3.5%]
Any other 
mixed/black 
background
0/43 (0%)
[0%, 0%]
7/240 (2.9%)
[0.8%, 5.0%]
0/135 (0%)
[0%, 0%]
Ethnicity not 
stated
2/43 (4.7%) [-1.6%, 
10.9%]
4/240 (1.67%)
[0.0%, 3.3%]
1/135 (0.7%)
[-0.7%, 2.2%]
0.100
Ethnicities were compared between age groups using the Chi Square test of independence. For 
each ethnic group, the total number of patients is provided along with the percentage (in curved 
brackets), and 95% confidence intervals for the percentage [in square brackets].
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Supplement table 2: Distribution of ethnicities across age groups.
Differences in ethnical compositions among sub-cohorts was tested using Chi square tests.
Age groups White Caucasian Asian Afro-Caribbean No of individuals P value
≤7 20 (48.8%) 13 (31.7%) 8 (19.5%) 41
8 to 13 111 (47.0%) 74 (31.4%) 51 (21.6%) 236
≥14 79 (59.0%) 41 (30.6%) 14 (10.4%) 134 0.072
No of 
individuals 210 127 74 411
Page 22 of 21
http://mc.manuscriptcentral.com/lupus
LUPUS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
